Toggle light / dark theme

This might be important. It might not be over for metformin just yet though as a mice study showed that rapamycin combined with metformin removed each other’s side effects.


If you are a non-diabetic who takes metformin for longevity, I highly recommend you stop immediately. Hear me out, and at the end of the video I’ll share what to do instead.

My full supplement stack: https://drstanfield.com/my-supplements/

From the beginning, our group has been about coming together to talk about crypto in a safe space. To share tips in a respectful and honest environment where people can make like-minded friends in an inclusive environment. We desire to educate, as well as learn in this ever changing landscape that is crypto. Moving forward we will grow whilst considering our core values.

For more information follow our official socials:
Main TG: https://t.me/whalecointalk.
News TG: https://t.me/whalecointalknews.
Twitter: https://twitter.com/WhaleCoinTalk.
Website: https://www.whalecointalk.com.
Instagram: https://www.instagram.com/whalecointalkofficial.

Disclaimer:
Not Financial Advice.
Do Your Own Research.

#Binance #BNB #Bitcoin #Ethereum #Doge #Shiba #Cryptocurrency #AMA #AskMeAnything #NFTs #MetaVerse #Kishu #Blockchain #DeFi #CryptoAMA

Dr Vittorio Sebastiano presents about aging and reprogramming and answers questions from audience in this clip. He specifies short Reprogramming does not impact cellular Identity but Impact cellular age and cellular health.

Dr. Vittorio Sebastiano is an Assistant Professor in the Department of Obstetrics and Gynecology at Stanford School of Medicine. His lab has established a new technology named ERA (Epigenetic Reprogramming of Aging), which repurposes the conceptual idea of reprogramming, with the goal to promote epigenetic rejuvenation of adult cells leaving their identity untouched. This new technology was patented and is being implemented by Turn Biotechnologies, of which Dr. Sebastiano is co-founder and Chair of the Scientific Advisory Board.

In 2009, Dr. Sebastiano completed a postdoctoral fellowship at the laboratory of Dr. Marius Wernig at Stanford University, where he implemented the newly discovered iPSC technology and was among the first to demonstrate that iPSCs can be efficiently derived, genetically modified, and implemented for cell therapy in genetic diseases (Sebastiano et al., 2014, Science Translational Medicine).
Dr. Sebastiano completed his undergraduate and graduate studies at the University of Pavia, Italy, where he studied murine germ cells and preimplantation development and where he pioneered cellular reprogramming by Somatic Cell Nuclear Transfer. He joined the Max Planck Institute for Molecular Biomedicine as a postdoctoral fellow under the mentorship of Dr. Hans Robert Schöler, where he continued his research on cellular reprograming, germ cells biology, and embryonic development.

DISCLAIMER: Please note that none of the information in this video constitutes health advice or should be substituted in lieu of professional guidance. The video content is purely for informational purposes.

Some health conditions associated with appeared early and consistently long before diagnosis, while others became significant much later, a cohort study suggested.

For people with a subsequent diagnosis of Alzheimer’s disease, the earliest and most consistent associations at all time points over a 15-year span included depression, erectile dysfunction, gait abnormalities, hearing loss, and nervous and musculoskeletal symptoms, reported Lori Beason-Held, PhD, of the National Institute on Aging in Baltimore, and co-authors.

For those eventually diagnosed with vascular, the earliest and most consistent associations across 13 years were an abnormal electrocardiogram (EKG), cardiac dysrhythmias, cerebrovascular disease, non-epithelial skin cancer, depression, and hearing loss, the researchers reported in Annals of Neurology.

Dr. Aubrey de Grey is a legend in the longevity field who has been steadfastly promoting the idea of life extension since well before it became mainstream. While with SENS Research Foundation, de Grey made significant contributions to geroscience, and at Longevity Summit Dublin last year, he announced the creation of his new brainchild, Longevity Escape Velocity Foundation (LEVF).

Now, the first major and long-awaited LEVF-funded project is being launched: Robust Mouse Rejuvenation (RMR). This is envisioned as a rolling research program aiming to increase both the mean and maximum lifespan of mice by at least 12 months with various combination therapies started late in life. For the first study, four therapies have been chosen: rapamycin, a senolytic, hematopoietic stem cell transplantation (HSCT), and telomerase expression. A groundbreaking experiment by any measure, RMR got us excited, and we reached out to Aubrey to discuss both RMR and LEVF in depth.

The following interview has Arkadi asking questions in bold and Aubrey de Grey answering in normal font.